Codexis, Inc.
Codexis, Inc. (CDXS) is a protein engineering company that designs and commercialises engineered enzymes for pharmaceutical development, biocatalysis and industrial applications. Investors should know Codexis operates a platform-led model: its proprietary CodeEvolver® technology seeks to speed enzyme discovery and optimisation, which the company monetises via collaborations, licensing and product sales. Revenue drivers include partnerships with large drugmakers, royalties from licensed programmes and productised enzyme offerings. As a small-cap biotech (market cap ~ $249M) the stock can be sensitive to partnership updates, development milestones and quarterly results. Strengths include strong scientific IP and established commercial deals, but risks include dependence on a limited number of partners, competitive enzyme technologies, and the general volatility of the biotech sector. This summary is educational and not personal advice; potential investors should assess suitability, consider diversification, and be aware that past performance is not a reliable guide to future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Codexis stock, believing it could rise significantly in value.
Financial Health
Codexis is performing well with strong revenue and cash flow, showing good profit potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CDXS
Synthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform-driven Growth
CodeEvolver® aims to accelerate enzyme discovery, supporting collaborations and licences that can drive revenue — though commercial uptake can take time.
Partner-led Commercial Model
Codexis often monetises through partnerships and royalties with large pharma and industrial customers, which can provide scalable opportunities but also concentration risk.
Small-cap Volatility Risk
Market moves can be pronounced for small biotechnology firms; investors should consider suitability and diversification before taking a position.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
